AmVision Biotech Secures Nearly $14.34M in Series A+ for Ophthalmology Innovations
AmVision Biotech, a leading ophthalmology device platform company based in Guangzhou, has reportedly secured close...
JW Therapeutics Launches Carteyva Clinical Study for High-Risk Lymphoma
China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its...
Chongqing Evaheart Secures Near $100M in Series A for Heart Failure Platform
Chongqing Evaheart Medical Device Co., Ltd has reportedly secured close to USD 100 million in...
Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing...
Haihe Pharma’s Glumetinib Receives Conditional Approval for NSCLC Treatment
Shanghai Haihe Pharmaceutical Co., Ltd’s Category 1 product, glumetinib, has obtained conditional market approval from...
AmVision Biotech Secures RMB 100 Million in Series A+ Financing for Ophthalmology Innovation
AmVision Biotech, an ophthalmology device platform company based in Guangzhou, has reportedly raised close to...
JW Therapeutics Initiates Clinical Study for Carteyva in First-Line High-Risk Large B-Cell Lymphoma
China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its...
Evaheart Med Raises USD 100 Million in Series A Funding Led by Sinovac
Chongqing Evaheart Medical Device Co., Ltd has reportedly raised close to USD 100 million in...
HQ Pharma and Shanxi HCXF Partner to Expand Oral Soluble Film R&D and Production
China-based firms HQ Pharma and Shanxi HCXF Pharmaceutical Co., Ltd have agreed to jointly expand...
Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing...
Sumitomo Pharma Secures Rights to Vibegron for Asian Markets
Japan-based Sumitomo Pharma Co., Ltd has signed a sub-license deal with compatriot firm Kyorin Pharmaceutical...
Suzhou Porton Biologics Partners with Bennu Biotherapeutics for Gene and Cell Therapies
China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...
Akeso Biopharma and Shanghai Pharmaceuticals Collaborate on Liposarcoma Treatment
China-based Akeso Biopharma (HKG: 9926) has announced a strategic collaboration agreement with compatriot firm Shanghai...
F-star Therapeutics’ Acquisition by invoX Pharma Cleared by CFIUS
UK biotech F-star Therapeutics, Inc. (NASDAQ: FSTX) has announced that it has received clearance from...
Biocytogen’s YH008 Gets NMPA Approval for Phase I Study
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced receiving approval from the China National Medical...
Heranova Closes $10M Seed Round for Women’s Health Solutions
Heranova Lifesciences Holding, a provider of women’s health solutions, has announced the successful closure of...
Inmagene’s Tavalisse First Prescribed in China for ITP Treatment
China-based Inmagene Biopharmaceuticals has announced that its in-licensed drug Tavalisse (fostamatinib) has been first prescribed...
AusperBio Initiates Phase I Trial for AHB-137 in New Zealand
Sino-US liver therapy developer AusperBio has announced the initiation of the first cohort dosing in...
China’s Party and State Institutions Reshuffle: Key Changes for Healthcare and Finance
The second plenary session of the 20th Communist Party of China (CPC) Central Committee has...
BrightGene’s Generic Halaven Approved for Marketing in China
China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has received marketing approval from the National...